Renal Cancer Drugs Market by Type (Clear Cell, Papillary, Chromophobe, Oncocytic, Collecting Duct), Brand (Sutent, Nexavar, Afinitor, Votrient, Inlyta, Avastin, Torisel, Proleukin) - Analysis and Global Forecast to 2019
Renal cancer commonly known as kidney cancer originates in the lining of the proximal convoluted tubule of the kidney. The renal cancer is caused by Von Hippel-Lindau (VHL) syndrome, obesity, smoking, high blood pressure, long-term dialysis, occupational exposure (for example asbestos workers). The symptoms of renal cancer include a lump or mass in the abdomen or side, blood in the urine, weight loss, fever, and lethargy. Several drugs for the treatment of renal cancer are currently available in the market.
The global renal cancer drug market is likely to show significant growth during the forecast period. This is attributed to the rising incidences of renal cancer, increasing geriatric population, and approval of novel molecules to develop drugs. However, high prices of branded drugs to treat cancer and rising preference for generic drugs are expected to restrain the market for renal cancer drugs market.
Categories of Renal Cancer Drugs
The renal cancer drugs market is segmented into three broad categories: by type, by brand, and by geography. Based on type, the market is divided into clear cell, papillary (Types 1 and 2), chromophobe, oncocytic, and collecting duct. The renal cancer drugs market, by brand is categorized into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus), Proleukin (Aldesleukin), and others.
The renal cancer drugs market is segmented into three broad categories: by type, by brand, and by geography. Based on type, the market is divided into clear cell, papillary (Types 1 and 2), chromophobe, oncocytic, and collecting duct. The renal cancer drugs market, by brand is categorized into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus), Proleukin (Aldesleukin), and others.
Geographically Region
The global renal cancer drugs market is segmented into North America, Europe, Asia and Rest of the World (RoW: Latin America, Pacific Countries, and Middle East & Africa). North America accounted for the largest share of global renal cancer drugs, by region in 2014. However, Asia is expected to be the fastest growing market during the forecast period.
The global renal cancer drugs market is segmented into North America, Europe, Asia and Rest of the World (RoW: Latin America, Pacific Countries, and Middle East & Africa). North America accounted for the largest share of global renal cancer drugs, by region in 2014. However, Asia is expected to be the fastest growing market during the forecast period.
Key Players
Some of the major players in the global renal cancer drugs market include Active Biotech AB (Sweden), Amgen (U.S.), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Onyx Pharmaceuticals Inc. (U.S.), Pfizer, Inc. (U.S.).
Some of the major players in the global renal cancer drugs market include Active Biotech AB (Sweden), Amgen (U.S.), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Onyx Pharmaceuticals Inc. (U.S.), Pfizer, Inc. (U.S.).
To know about the assumptions considered for the study, download the pdf brochure
Comments
Post a Comment